Next-Generation Biotech Innovations

Approach: CCR5 Blockade + PD-L1 Modulation + Broadly Neutralizing Antibodies (bNAbs)

Indication: HIV Cure Protocol

Stage: Preclinical

FireGate Biotech is advancing a bold pipeline beginning with HIV. By leveraging CCR5 biology, PD-L1 modulation, and AI-driven insights, we are repurposing proven therapies while designing new ones  accelerating the path toward a functional cure.

Approach: AI-Repurposed Immunotherapy

Indication: Triple-Negative Breast Cancer (mTNBC)

Stage: Discovery

FG-002 is an early-stage oncology program exploring AI-driven immunotherapy repurposing strategies. FireGate is evaluating combinations designed to enhance immune activation and overcome tumor resistance in mTNBC.

Approach: AI-Driven Immunomodulation

Indication: Multiple Sclerosis (MS)

Stage: Discovery

FG-003 explores novel immunotherapy strategies guided by artificial intelligence to address autoimmune disorders, beginning with Multiple Sclerosis. This program is designed to rebalance immune activity and reduce disease progression in a condition that still lacks curative treatments.

Running a holiday sale or weekly special? Definitely promote it here to get customers excited about getting a sweet deal.